Reach Us +44-1904-929220
SOX9: From Biomarker To A Therapeutic Target In Breast Cancer | 3635

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

SOX9: From biomarker to a therapeutic target in breast cancer

2nd World Congress on Biomarkers & Clinical Research

Geetika Chakravarty

Posters: J Mol Biomark Diagn

DOI: 10.4172/2155-9929.S1.3

Typically, there is a time gap of two to three weeks between a biopsy proven diagnosis of cancer and surgical intervention, at which time the physician has access to the same tumor tissue again. If a biomarker can diff erentially diagnose and predict the prognosis of the disease, the physician has the option of adding adjunct therapy to enhance the therapeutic effi cacy of surgical intervention. Furthermore, if this biomarker can be targeted using a cocktail of drugs that induce diff erentiation of cancer cells (retinoids etc.) one may be able to monitor the therapeutic effi cacy of this approach by analyzing the surgical specimen for markers of diff erentiation and compare the outcome with that of the initial biopsy specimen. In this talk I will summarizes our work on one such novel biomarker: SOX9, our eff orts to induce diff erentiation of poorly diff erentiated breast cancer cells through nuclear translocation of this biomarker with an HDAC inhibitor and modulation of its post translational function. I will conclude the talk with studies that show how monitoring of this biomarker is inexpensive, yet can yield much insight about the biology of the disease and how this information can be useful in choosing the right therapeutic approach
Dr. Chakravarty completed her Ph.D from Tata Memorial Hospital, University of Mumbai, India and postdoctoral studies from Baylor College of Medicine, USA. She is looking for collaborators to test SOX9?s biomarker potential. She is an Instructor in the School of Medicine, Tulane University. She has published in reputed cancer journals and is serving as an editorial board member of repute.
Relevant Topics